The growth inhibitory effect of 17-DMAG on ALK and MYCN double-positive neuroblastoma cell line

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3229-3235

  Yi, Bin ^a,b   Yang, Jixin ^a,b   Wang, Lizhong ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

17 DMAG; ALK; MYCN; Neuroblastoma; Tumor cell growth

Indexed keywords

ALVESPIMYCIN; ANAPLASTIC LYMPHOMA KINASE;

APOPTOSIS; ARTICLE; CANCER GROWTH; CELL CYCLE ARREST; CELL VIABILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; ONCOGENE C MYB; PRIORITY JOURNAL; PROTEIN EXPRESSION; WESTERN BLOTTING;

BENZOQUINONES; CELL LINE, TUMOR; CELL PROLIFERATION; HSP90 HEAT-SHOCK PROTEINS; HUMANS; LACTAMS, MACROCYCLIC; NEUROBLASTOMA; NUCLEAR PROTEINS; ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES;

EID: 84898825284     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1422-7     Document Type: Article

References (30)

1. Riley RD, Heney D, Jones DR, Sutton AJ, Lambert PC, Abrams KR, et al. A systematic review of molecular and biological tumor markers in neuroblastoma. Clin Cancer Res. 2004;10:4-12.
2. Hoehner JC, Gestblom C, Hedborg F, Sandstedt B, Olsen L, Pahlman S. A developmental model of neuroblastoma: differentiating stroma-poor tumors' progress along an extra-adrenal chromaffin lineage. Lab Invest. 1996;75:659-75.
3. Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol. 2001;54:897-910.
4. Maris JM. Recent advances in neuroblastoma. New Engl J Med. 2010;362:2202-11.
5. Cohn SL, Pearson AD, London WB, Monclair T, Ambros PF, Brodeur GM, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289-97.
6. Matthay KK, Villablanca JG, Seeger RC, Stram DO, Harris RE, Ramsay NK, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's cancer group. New Engl J Med. 1999;341:1165-73.
7. Schwab M, Ellison J, Busch M, Rosenau W, Varmus HE, Bishop JM. Enhanced expression of the human gene n-myc consequent to amplification of DNA may contribute to malignant progression of neuroblastoma. Proc Natl Acad Sci U S A. 1984;81:4940-4.
8. Schwab M. Mycn in neuronal tumours. Cancer Lett. 2004;204:179-87.
9. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA. The mycn oncogene and differentiation in neuroblastoma. Semin Cancer Biol. 2011;21:256-66.
10. Dang CV. Myc on the path to cancer. Cell. 2012;149:22-35.
11. George RE, Sanda T, Hanna M, Frohling S, Luther 2nd W, Zhang J, et al. Activating mutations in alk provide a therapeutic target in neuroblastoma. Nature. 2008;455:975-8.
12. Mosse YP, Laudenslager M, Longo L, Cole KA, Wood A, Attiyeh EF, et al. Identification of alk as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930-5.
13. Janoueix-Lerosey I, Lequin D, Brugieres L, Ribeiro A, de Pontual L, Combaret V, et al. Somatic and germline activating mutations of the alk kinase receptor in neuroblastoma. Nature. 2008;455:967-70.
14. Azarova AM, Gautam G, George RE. Emerging importance of alk in neuroblastoma. Semin Cancer Biol. 2011;21:267-75.
15. Chen Y, Takita J, Choi YL, Kato M, Ohira M, Sanada M, et al. Oncogenic mutations of alk kinase in neuroblastoma. Nature. 2008;455:971-4.
16. Ogawa S, Takita J, Sanada M, Hayashi Y. Oncogenic mutations of alk in neuroblastoma. Cancer Sci. 2011;102:302-8.
17. Carpenter EL, Mosse YP. Targeting alk in neuroblastoma - preclinical and clinical advancements. Nat Rev Clin Oncol. 2012;9:391-9.
18. De Brouwer S, De Preter K, Kumps C, Zabrocki P, Porcu M, Westerhout EM, et al. Meta-analysis of neuroblastomas reveals a skewed alk mutation spectrum in tumors with mycn amplification. Clin Cancer Res. 2010;16:4353-62.
19. Berry T, Luther W, Bhatnagar N, Jamin Y, Poon E, Sanda T, et al. The alk(f1174l) mutation potentiates the oncogenic activity of mycn in neuroblastoma. Cancer Cell. 2012;22:117-30.
20. Zhu S, Lee JS, Guo F, Shin J, Perez-Atayde AR, Kutok JL, et al. Activated alk collaborates with mycn in neuroblastoma pathogenesis. Cancer Cell. 2012;21:362-73.
21. Schonherr C, Ruuth K, Kamaraj S, Wang CL, Yang HL, Combaret V, et al. Anaplastic lymphoma kinase (ALK) regulates initiation of transcription of mycn in neuroblastoma cells. Oncogene. 2012;31:5193-200.
22. Pacey S, Wilson RH, Walton M, Eatock MM, Hardcastle A, Zetterlund A, et al. A phase I study of the heat shock protein 90 inhibitor alvespimycin (17-dmag) given intravenously to patients with advanced solid tumors. Clin Cancer Res. 2011;17:1561-70.
23. Kobayashi N, Toyooka S, Soh J, Yamamoto H, Dote H, Kawasaki K, et al. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-dmag, on non-small-cell lung cancers being resistant to egfr tyrosine kinase inhibitor. Lung Cancer. 2012;75:161-6.
24. Hollingshead M, Alley M, Burger AM, Borgel S, Pacula-Cox C, Fiebig HH, et al. In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17- demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative. Cancer Chemother Pharmacol. 2005;56:115-25.
25. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, et al. Stage 1 testing and pharmacodynamic evaluation of the hsp90 inhibitor alvespimycin (17-dmag, kos-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;51:34-41.
26. Jhaveri K, Miller K, Rosen L, Schneider B, Chap L, Hannah A, et al. A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (kos-1022; 17 dmag) in the treatment of advanced solid tumors. Clin Cancer Res. 2012;18:5090-8.
27. Regan PL, Jacobs J, Wang G, Torres J, Edo R, Friedmann J, et al. Hsp90 inhibition increases p53 expression and destabilizes mycn and myc in neuroblastoma. Int J Oncol. 2011;38:105-12.
28. Chen Z, Sasaki T, Tan X, Carretero J, Shimamura T, Li D, et al. Inhibition of alk, pi3k/mek, and hsp90 in murine lung adenocarcinoma induced by eml4-alk fusion oncogene. Cancer Res. 2010;70:9827-36.
29. Cheung NK, Dyer MA. Neuroblastoma: developmental biology, cancer genomics and immunotherapy. Nat Rev Cancer. 2013;13:397-411.
30. Schulte JH, Lindner S, Bohrer A, Maurer J, De Preter K, Lefever S, et al. Mycn and alkf1174l are sufficient to drive neuroblastoma development from neural crest progenitor cells. Oncogene. 2013;32:1059-65.